Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II
NCT ID: NCT03402711
Last Updated: 2018-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
5500 participants
OBSERVATIONAL
2017-12-14
2021-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
NCT06955143
A Registry Study on Genetics and Biomarkers of Acute Coronary Syndrome
NCT03752515
A Cohort of Patients Undergoing Percutaneous Coronary Intervention
NCT05719545
Evaluation of C13 Breath Test for Upper Gastrointestinal Bleeding in Patients Who Need Double Antiplatelet After PCI
NCT04012801
Bleeding Risk Assessment System for Antithrombotic Therapy of ACS
NCT04162808
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
With the development of antithrombotic drugs and percutaneous coronary interventional therapy, bleeding has become one of the major complications for ACS patients after PCI.Moreover,Bleeding after PCI therapy significantly increased short-term and long-term risk of death.
However, there is a lack of data on the risk of bleeding in ACS patients treated with PCI in the clinical reality world of china.
Therefore,the present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI.
The present study was designed to observe the incidence of bleeding events and characteristics of bleeding and exploratively analyse bleeding related biomarkers and gene polymorphisms in ACS patients undergoing PCI.
This study will provide sufficient and reliable evidence for the risk of bleeding and the choice of antithrombotic drugs in ACS patients undergoing PCI in China, and provide a reference for individual antithrombotic therapy after PCI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bleeding Risk in Chinese ACS II
1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* confirmed acute coronary syndrome patients;
* undergo percutaneous coronary intervention (PCI) treatment;
* agree to participate in this clinical study and sign a written consent form.
Exclusion Criteria
* patients who are not intend to attend 1 year of follow-up study or investigators find that patients are not able to comply with the study's requirements;
* pregnant women or lactating women;
* investigators consider patients who were not suitable for participation with other reasons
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yun Dai Chen
Director of the Cardiovascular Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yundai Chen, MD
Role: PRINCIPAL_INVESTIGATOR
The General Hospital of PLA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The General Hospital of PLA
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLOPIL08731
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.